Intro

This chapter explores the FDA's recent approval of Imetalstat for treating lower-risk myelodysplastic syndromes and transfusion-dependent anemia. Insights from the Phase III EMERGE trial reveal the drug's efficacy in improving red blood cell transfusion independence for patients unresponsive to previous treatments.